Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,884 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05599412Recruiting
Tracking safety of Lorviqua in ALK-positive lung cancer
This study is collecting real-world safety information about Lorviqua (lorlatinib) in adults in Korea who have ALK-positive metastatic non-small cell lung cancer. It helps monitor side effects and safe use after the medicine is already on the market.
SeoulAges 18 years+ - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT05530057RecruitingPhase 2
Eribulin plus or minus trastuzumab for HER2-positive breast cancer
This trial tests whether adding trastuzumab to eribulin improves outcomes for people with HER2-positive breast cancer that has come back or spread. It’s meant for patients whose cancer has progressed after prior HER2 and chemotherapy treatments.
SeoulAges 18 years+ - NCT04969354RecruitingPhase 1
CAIX-targeted CAR-T therapy for advanced kidney cancer
This early-phase study tests a lab-made immune treatment (CAIX-targeted CAR-T cells) for advanced kidney cancer that has not gone away with standard targeted therapy or immunotherapy. If eligible, the goal is to see if the treatment can safely shrink the cancer and improve outcomes.
Xuzhou, JiangsuAges 18–70 - NCT04685226RecruitingPhase 1/Phase 2
Testing ICP-723 for advanced solid tumors you can’t remove
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
Hefei, AnhuiAges 12 years+ - NCT04428671RecruitingPhase 1
Cemiplimab before and after surgery for high-risk skin cancer
This Phase 1 trial tests the drug cemiplimab given before and after surgery to reduce the chance that high-risk cutaneous squamous cell cancer comes back. You may be a candidate if your cancer is high-risk on pathology or imaging and is planned for surgical removal.
Atlanta, GeorgiaAges 18 years+ - NCT04219254RecruitingPhase 1/Phase 2
Testing BI-1206 with pembrolizumab for advanced solid cancers
This early-phase trial studies BI-1206 together with pembrolizumab to treat advanced solid tumors. It may be an option if your cancer has progressed after prior anti–PD-1/PD-L1 treatment (or, in some groups, if standard treatments aren’t suitable).
Los Angeles, CaliforniaAges 18 years+ - NCT04086290RecruitingPhase 1/Phase 2
Surgery plus targeted radiation for prostate cancer spread
This study looks at whether combining prostate surgery with a highly focused radiation treatment (SBRT) can control prostate cancer that has spread to a limited number of bones. It may help patients by treating the main tumor and the specific metastatic spots in a controlled way.
HerlevAges 18 years+ - NCT04109131Recruiting
Study platform for brain metastases in solid cancers
This trial studies people with solid tumors that have spread to the brain (including the brain lining) to help researchers learn what works and how best to treat it. You may be asked for blood/tissue samples and a procedure to collect spinal fluid when brain metastases are diagnosed.
AnderlechtAges 18 years+ - NCT05203913RecruitingPhase 2
Bladder cancer trial adds chemo, immunotherapy, and radiation after surgery
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
RomaAges 18 years+ - NCT02215928Recruiting
Using tumor genetic tests to guide treatment choices
This study looks at your tumor’s genetic information to help doctors recommend treatment for cancers that have spread. It may help you get the most suitable therapy based on what’s found in your tumor.
Palo Alto, CaliforniaAges 18 years+ - NCT07671534RecruitingPhase 2
Metronomic chemotherapy with gemcitabine, mitomycin C, and thalidomide for advanced solid tumors
This trial tests a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in a low, frequent 'metronomic' schedule to treat advanced solid tumors that have already been treated. The goal is to see if this approach can slow or stop tumor growth with fewer side effects.
Santa Monica, CaliforniaAges 18 years+ - NCT07112209Enrolling by invitation
Rezvilutamide plus chemo for prostate cancer
This study tests a new combination treatment (Rezvilutamide plus docetaxel chemotherapy) for men with advanced prostate cancer that has stopped responding to abiraterone. The goal is to see if this combination can help control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT03488953Recruiting
Two-step liver surgery using a living donor transplant
This study looks at a specialized liver transplant approach using a living donor, for people with colorectal cancer that has spread only to the liver and cannot be removed by standard surgery. It’s meant for cases where chemotherapy has helped stop or shrink the tumors, to improve the chance of successful treatment.
JenaAges 18 years+ - NCT03692429RecruitingPhase 1
Testing new immune cells plus chemo for advanced colon cancer
This Phase 1 study tests CYAD-101, an immune-cell treatment made from donor T-cells, given with standard chemotherapy. It is for people with colon or rectal cancer that has spread and has not responded to prior treatments.
Tampa, FloridaAges 18 years+ - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT05701150Recruiting
Connects advanced solid-tumor patients to tumor gene data
This trial builds a large database using your existing tumor genetic test results (DNA and/or RNA). It may help researchers better understand advanced cancers and use gene patterns to guide future care.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06169956Recruiting
Study of nivolumab with chemo before lung cancer surgery
This study looks at how well the immunotherapy drug nivolumab (Opdivo) works when given with standard chemotherapy before surgery for people with a certain type of lung cancer that has not spread. It may help shrink the tumor before surgery.
Kempten (Allgäu), BavariaAges 18 years+ - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06141265RecruitingPhase 2
Niraparib maintenance after chemo and Avastin for advanced ovarian cancer
This trial tests whether the PARP inhibitor niraparib can help keep advanced ovarian cancer from coming back. You may qualify if you have a BRCA mutation or HRD-positive tumor and finished first-line chemotherapy with bevacizumab (Avastin) with good response.
Beijing, Beijing MunicipalityAges 18–75 - NCT06857279RecruitingPhase 2
Testing HLX43 for advanced head and neck cancer
This trial tests an investigational drug called HLX43 for people with advanced head and neck cancer that has returned or spread. It aims to see if the drug can shrink tumors or slow cancer growth.
Jinan, ShandongAges 18–75 - NCT06855134Recruiting
Genome-guided treatment for advanced rare cancers
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
AugsburgAges 18 years+
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,884 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.